Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094790 | 0.84 | SYK (0.40) | — | |
| SCHEMBL21889786 | 0.79 | CHRNB2 (0.47) | BRD4SLC6A2 | |
| SCHEMBL25408274 | 0.79 | FFAR4 (0.44) | FFAR4LOXL2PTGS1 | |
| SCHEMBL12949688 | 0.78 | PDGFRB (0.48) | BRD4MCHR1PDGFRBPDGFRAFFAR4 | |
| SCHEMBL27098424 | 0.78 | BRD4 (0.47) | BRD4MCHR1PDGFRBPDGFRAFFAR4 | |
| SCHEMBL25465488 | 0.77 | CNR2 (0.46) | MCHR1 | |
| SCHEMBL23467572 | 0.76 | NPY1R (0.48) | — | |
| SCHEMBL2144242 | 0.75 | MCHR1 (0.56) | BRD4MCHR1PDGFRBPDGFRAFFAR4 | |
| SCHEMBL31581118 | 0.75 | MCHR1 (0.42) | BRD4MCHR1PDGFRBPDGFRAFFAR4 | |
| SCHEMBL958367 | 0.75 | MCHR1 (0.45) | BRD4MCHR1PDGFRBPDGFRAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | BRD4 1582/4885MCHR1 4749/4885PDGFRB 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.